Biolidics Limited reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SGD 1.04 million compared to SGD 0.608 million a year ago. Net loss was SGD 6.21 million compared to SGD 1.76 million a year ago. Basic loss per share from continuing operations was SGD 0.0188 compared to SGD 0.0066 a year ago. Diluted loss per share from continuing operations was SGD 0.0188 compared to SGD 0.0066 a year ago.
For the full year, sales was SGD 2.49 million compared to SGD 2.31 million a year ago. Net loss was SGD 9.37 million compared to SGD 5.98 million a year ago. Basic loss per share from continuing operations was SGD 0.0333 compared to SGD 0.0226 a year ago. Diluted loss per share from continuing operations was SGD 0.0333 compared to SGD 0.0226 a year ago.